Regulation of Tau Pathology by the Microglial Fractalkine Receptor  by Bhaskar, Kiran et al.
Neuron
ArticleRegulation of Tau Pathology by the
Microglial Fractalkine Receptor
Kiran Bhaskar,1 Megan Konerth,1 Olga N. Kokiko-Cochran,1 Astrid Cardona,1,3 Richard M. Ransohoff,1
and Bruce T. Lamb1,2,*
1Department of Neurosciences, Lerner Research Institute, Cleveland Clinic Foundation, NC30/9500 Euclid Avenue,
Cleveland, OH 44195, USA
2Department of Genetics and Neurosciences, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA
3Present address: Department of Biology, University of Texas San Antonio, TX 78249, USA
*Correspondence: lambb@ccf.org
DOI 10.1016/j.neuron.2010.08.023SUMMARY
Aggregates of the hyperphosphorylated micro-
tubule-associated protein tau (MAPT) are an in-
variant neuropathological feature of tauopathies.
Here, we show that microglial neuroinflammation
promotes MAPT phosphorylation and aggregation.
First, lipopolysaccharide-induced microglial activa-
tion promotes hyperphosphorylation of endogenous
mouse MAPT in nontransgenic mice that is further
enhanced in mice lacking the microglial-specific
fractalkine receptor (CX3CR1) and is dependent
upon functional toll-like receptor 4 and interleukin-1
(IL-1) receptors. Second, humanized MAPT trans-
genic mice lacking CX3CR1 exhibited enhanced
MAPT phosphorylation and aggregation as well as
behavioral impairments that correlated with in-
creased levels of active p38 MAPK. Third, in vitro
experiments demonstrate that microglial activation
elevates the level of active p38 MAPK and enhances
MAPT hyperphosphorylation within neurons that can
be blocked by administration of an interleukin-1
receptor antagonist and a specific p38 MAPK inhib-
itor. Taken together, our results suggest that
CX3CR1 and IL-1/p38 MAPK may serve as novel
therapeutic targets for human tauopathies.
INTRODUCTION
Increasing evidence suggests that neuroinflammation is
a common feature of tauopathies. First, activated microglia are
found in the postmortem brain tissues of various human tauopa-
thies including Alzheimer’s disease (AD), frontotemporal
dementia (FTD), progressive supranuclear palsy and cortico-
basal degeneration (Gebicke-Haerter, 2001; Gerhard et al.,
2006; Ishizawa and Dickson, 2001). Second, induction of
systemic inflammation via administration of the Toll-like receptor
4 (TLR4) ligand, lipopolysaccharide (LPS) significantly induced
MAPT hyperphosphorylation in a triple transgenic mouse model
of AD (Kitazawa et al., 2005). Third, the immunosuppressant drug
FK506 attenuated microglial activation and extended the lifespan of P301S transgenic mouse model of FTD (Yoshiyama
et al., 2007). Finally, a growing number of studies suggest that
proinflammatory cytokines, such as interleukin-1 (IL-1), inter-
leukin-6, and nitric oxide released from astrocytes can accel-
erate MAPT pathology and formation of neurofibrillary tangles
(NFTs) in vitro (Li et al., 2003; Quintanilla et al., 2004; Saez
et al., 2004). While these findings suggest a correlative link
between neuroinflammation and tauopathies, there is little
mechanistic evidence that altered microglial activation plays
a pathogenic role in the formation of MAPT pathologies.
Recent experimental evidence has directly implicated micro-
glia in the pathogenesis of a variety of neurodegenerative dis-
eases, including Parkinson’s disease (PD), amyotrophic lateral
sclerosis (ALS), and a mouse model of systemic inflammation.
One signaling pathway through which neurons and microglia
communicate and has been demonstrated to play an important
role in neuroinflammation and neuroprotection is fractalkine
(CX3CL1) and its cognate receptor (CX3CR1), a unique, one-
to-one ligand-receptor chemokine pair. Notably, CX3CL1 is
highly expressed in neurons while CX3CR1 is exclusively ex-
pressed in microglia within the CNS (Harrison et al., 1998).
Furthermore, exogenously added CX3CL1 is neuroprotective in
models of in vitro neuroinflammation (Meucci et al., 1998;Mizuno
et al., 2003). In addition, a genetic variant with reduced levels of
CX3CR1 has been associated with age-related macular degen-
eration in humans (Combadiere et al., 2007). Notably, disruption
of CX3CL1-CX3CR1 signaling by deletion of the Cx3cr1 gene
induces neurotoxicity in mouse models of systemic inflamma-
tion, PD, and ALS (Cardona et al., 2006) but is protective against
neuronal loss in a mouse model of focal cerebral ischemia
(Denes et al., 2008) and in the triple transgenic (3xTg) mouse
model of AD (Fuhrmann et al., 2010). However, the CX3CR1-
deficient 3xTg animals were examined at an age prior to the
development of either extracellular Ab deposition or intracellular
MAPT aggregation that defines AD and thus the nature of the
signal that leads to the neurotoxicity in this model that is pro-
tected by CX3CR1 deficiency is unclear. Finally, we recently
observed that CX3CR1 deficiency leads to reduced Ab deposi-
tion in two different transgenic mouse models of AD, potentially
through enhanced uptake of fibrillar Ab by CX3CR1-deficient mi-
croglia (Lee et al., 2010). Together, these studies demonstrate
that altered microglial signaling through CX3CR1 plays a direct
role in neurodegeneration and/or neuroprotection depending
upon the CNS insult.Neuron 68, 19–31, October 7, 2010 ª2010 Elsevier Inc. 19
Figure 1. Enhancement of Microglial Activation via Injection of LPS or Genetic Deletion of Cx3cr1 Promotes MAPT Hyperphosphorylation
(A) Schematic diagram showing that 2-month-oldCx3cr1+/+orCx3cr1/micewere injectedwith a single dose of L-LPS (1.0mg/kg b.w; i.p.) or H-LPS (10.0mg/kg
b.w; i.p) or vehicle (Veh), sacrificed after 24 hr and brains processed either for biochemical or immunohistochemical analysis.
(B) Western immunoblot of hippocampal extracts shows LPS induces dose-dependent increases in AT8 (ser202) and AT180 (thr231) site phosphorylation of
endogenousmouseMAPT inCx3cr1+/+mice,whichwas further elevated inCx3cr1/mice injectedwith L-LPSorH-LPS. TotalMAPTandglyceraldehyde3-phos-
phate dehydrogenase (GAPDH) levels were similar across all samples.
(C and D) Quantification of western blots revealed a statistically significant (n = 4 for Cx3cr1+/+ with Veh; n = 5 for Cx3cr1+/+ with L-LPS; n = 4 for Cx3cr1/ with
L-LPS; n = 3 for Cx3cr1+/+with H-LPS and n = 3 for Cx3cr1/with H-LPS; mean ± SEM of integrated density value – IDV ratio; *p < 0.05; **p < 0.01; ***p < 0.001;
one-way ANOVA with Tukey multiple comparison post hoc test) increase in the AT8/Total MAPT and AT180/Total MAPT with H-LPS treatment of wild-type mice
and an even greater increase in LPS-injected Cx3cr1/mice.
(E–H) Double immunofluorescence revealing Iba1+ morphological activation of microglia (green) and AT8 + neurons (red) in wild-type mice injected with LPS that
was further enhanced in LPS-injected Cx3cr1/mice. Scale bar, 10 mm.
See also Figure S1.
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Regulation of tau Pathology by CX3CR1In the current studies, we evaluated the effects of either
LPS administration and/or CX3CR1 deficiency on MAPT hyper-
phosphorylation, and aggregation in both nontransgenic mice
and in a humanized mouse model of tauopathy (hTau). LPS
administration induced hyperphosphorylation of both endoge-
nous and transgene-derived MAPT that was dependent upon
LPS dose and CX3CR1 deficiency. Furthermore, introduction
of CX3CR1 deficiency into hTau mice resulted in altered
microglial activation, enhanced MAPT phosphorylation and
aggregation, as well as behavioral abnormalities. Finally, we
provide mechanistic data suggesting that the pathways respon-
sible for these effects include microglial-derived interleukin-1
(IL-1) and neuronal p38 mitogen-activated protein kinase
(MAPK). These results suggest a direct link between microglial
activation and MAPT phosphorylation and aggregation within
neurons.20 Neuron 68, 19–31, October 7, 2010 ª2010 Elsevier Inc.RESULTS
Enhanced MAPT Phosphorylation after Systemic LPS
Administration
To study the relationship between microglial activation and
phosphorylation of endogenous mouse MAPT, 2-month-old
C57BL/6 mice were exposed to an inflammatory stress via
peripheral administration of either low (1 mg/kg; intraperitoneal)
or high (10 mg/kg; i.p) dose of LPS and the brain extracts were
prepared for western blot analysis (Figure 1A). With increasing
concentrations of LPS, there were elevated levels of mouse
MAPT phosphorylated at both ser202 (AT8) and thr231 (AT180)
in brain extracts when compared with the vehicle-injected group
(Figures 1B–1D). In addition, there were increases in other phos-
phorylatedMAPT epitopes, including ser396/ser404 (PHF1, data
not shown).
Neuron
Regulation of tau Pathology by CX3CR1To examine the effects of further enhancing microglia activa-
tion on MAPT phosphorylation, we utilized Cx3cr1/ mice.
Previous studies demonstrated that loss of Cx3cr1 promotes
microglial activation and neurodegeneration in mouse models
of PD, ALS, as well as in systemic inflammation induced by
LPS (Cardona et al., 2006). Notably, LPS administration to
Cx3cr1/ mice resulted in a dramatic, dose-dependent eleva-
tion in phosphorylation of endogenous mouse MAPT at both
the AT8 and AT180 (Figures 1B–1D), as well as at PHF1 (data
not shown), sites when compared with nontransgenic controls
and vehicle-injected Cx3cr1/ mice (data not shown). To
confirm the biochemical data, fluorescent immunohistochem-
istry was performed on mouse brain sections revealing the pres-
ence of AT8+ cells within the dentate gyrus of LPS administered
nontransgenic mice when compared with vehicle-injected
controls (Figures 1E–1G) that was further enhanced in the
Cx3cr1/ mice (Figure 1H). These findings demonstrate that
LPS induces elevated endogenous MAPT phosphorylation that
is dependent upon LPS dose and the presence/absence of
CX3CR1.
Alterations in Microglial Activation in hTau Mice
To examine whether altered microglial activation was observed
in a mouse model of tauopathy, transgenic mice in which the
wild-type human MAPT gene replaced the endogenous mouse
Mapt gene (hTau mice) were examined for the age-related
appearance of MAPT pathology and microglial activation. hTau
mice first develop hyperphosphorylated MAPT at 3 months of
age, MAPT aggregates at 9 months and neuronal loss by
15 months of age (Andorfer et al., 2003). Notably, by about
12 months of age, hTau mice exhibited Iba1+ microglia in the
hippocampus with shorter processes and rounder cell bodies
consistent with microglial activation (Figure S1B) that was even
more pronounced in 18-month-old hTau mice (Figure S1C). By
contrast, nontransgenic mice at 18 months of age exhibited
Iba1+ microglia that were more ramified in appearance, consis-
tent with a quiescent phenotype (Figure S1A).
To support the immunohistochemistry results, the levels of
various cytokines and chemokines were also examined in the
hTau mice by ELISA. Notably, by as early as 6 months of age,
the levels of cleaved CX3CL1 were substantially elevated in
hippocampal extracts from hTaumicewhen comparedwith non-
transgenic controls (Figure S1H), whereas the levels of other
cytokines (TNF-a, INF-g, IL-1b, IL-6) remained unchanged
(data not shown). Furthermore, analysis of the levels of additional
chemokine/cytokine transcripts via quantitative real-time PCR
revealed elevated levels of both NOS2 and MCP1/CCL2 tran-
scripts in hemibrains of 6-month-old hTau mice when compared
with age-matched controls (Figures S1I–S1J). Taken together,
these results suggest that altered age-related alterations in neu-
roinflammation are observed in hTau mice at early stages of
disease progression, including the production of CX3CL1, the
ligand for the microglial receptor, CX3CR1.
Enhanced MAPT Phosphorylation in LPS-Injected
hTau Mice
To test whether further enhancing microglial activation in the
hTau mice could promote MAPT hyperphosphorylation,2-month-old hTau mice (prior to the first appearance of hyper-
phosphorylated MAPT in this model) were peripherally adminis-
tered with a low-dose (1 mg/kg; i.p) of LPS. LPS induced MAPT
hyperphosphorylation at the phospho-thr231 (TG3) and AT8
epitopes in the hippocampus of hTau mice (Figures S1E and
S1G) when compared with vehicle-injected hTau mice (Figures
S1D and S1F). Considering that the somatodendritic accumula-
tion of AT8+ MAPT does not occur until 3 months in the hippo-
campus of hTau mice (Andorfer et al., 2003), these results
suggest that induction of TLR4-mediated systemic inflammation
via LPS induces MAPT hyperphosphorylation in prepathological
hTau mice.
Worsened Disease in hTau-Cx3cr1–/– Transgenic Mice
LPS exerts its effects through TLR4 signaling in astrocytes,
endothelial cells, polydendrocytes, andmicroglia. To specifically
examine the role of microglial signaling in modulating MAPT
pathologies, hTaumice were mated with mice lacking the micro-
glial receptor, CX3CR1. Given our findings that CX3CR1 defi-
ciency promotes phosphorylation of MAPT following peripheral
LPS administration in nontransgenic mice (Figure 1) and that
6-month-old hTau mice exhibit elevated levels of cleaved
CX3CL1 (Figure S1H), we postulated that a deficiency in
CX3CR1 would promote MAPT pathologies in the hTau mice.
Six-month-old hTau-Cx3cr1/ mice exhibited significantly
increased MAPT phosphorylation on AT8, AT180 and PHF1 sites
when compared with age-matched hTau mice (Figures 2A–2D),
while detergent-soluble total MAPT levels remained unchanged
(Figure 2E). Consistent with the biochemical studies, immunohis-
tochemical analysis revealed a marked increase in the total
number of AT8+ (Figures 2F–2M), CP13+, and AT180+ (Fig-
ures S2A and S2B) neurons in the dentate gyrus and CA3 regions
of hippocampus of hTau-Cx3cr1/ mice compared with hTau
miceornontransgenic controls. TheenhancementofMAPTphos-
phorylation in the hTau-Cx3cr1/ mice required both the hTau
transgene and loss of CX3CR1 signaling, as neither 6-month-
old Cx3cr1/ (Figures 2F–2M; Figure S2J) nor Cx3cl1/ mice
(data not shown) exhibited alterations in AT8, AT180, or PHF1
epitopes when compared with nontransgenic controls.
MAPT hyperphosphorylation is thought to be the initial step in
the formation of MAPT aggregates and NFTs in the human AD
brain (Greenberg and Davies, 1990). Typically, when MAPT
undergoes self-aggregation, it becomes detergent insoluble in
Sarkosyl (N-laurylsarcosine). To examine the effects of
CX3CR1 deficiency on MAPT aggregation in the hTau mice,
1% Sarkosyl hippocampal extracts were prepared from
6-month-old hTau-Cx3cr1+/+ and hTau-Cx3cr1/ mice (Green-
berg and Davies, 1990; Mocanu et al., 2008) to generate both
Sarkosyl-soluble and -insoluble MAPT (‘‘pretangles’’) fractions
(Mocanu et al., 2008). Western blot analysis of these fractions re-
vealed elevated levels of Sarkosyl insoluble MAPT in hTau-
Cx3cr1/ mice when compared with hTau mice (Figure 2N)
and that MAPT in the insoluble fraction was hyperphosphory-
lated at the AT8 site (Figure 2N).
To confirm the presence and examine the localization of insol-
ubleMAPT in the brains of in hTau-Cx3cr1/mice, Gallyas silver
staining, a standardmethod for the detection of MAPT pathology
(Braak and Braak, 1991), was performed. Strikingly, numerousNeuron 68, 19–31, October 7, 2010 ª2010 Elsevier Inc. 21
Figure 2. CX3CR1 Deficiency Induces MAPT Hyperphosphorylation and Aggregation in 6-Month-Old hTau Mice
(A) Western blot analysis of hippocampal lysates revealed an increase in MAPT phosphorylation at AT8, AT180, and PHF1 in hTau-Cx3cr1/mice, but no alter-
ations in total MAPT levels (antibody Tau5); GAPDH was loading control.
(B–E) Quantification of western blots for AT8, PHF1, AT180, and total MAPT revealed a statistically significant (n = 5 for hTau-Cx3cr1+/+; n = 5 for hTau-Cx3cr1/;
mean ± SEM of IDV; *p < 0.05; unpaired t test) increase in AT8 (B), AT180 (D), and PHF1 (C), but not detergent-soluble total MAPT (E) in hTau-Cx3cr1/ mice
compared with hTau-Cx3cr1+/+ mice.
(F–M) Immunohistochemistry revealed an increase in the number of AT8-positive neurons in the dentate gyrus (DG) (I) and CA3 (M) in hTau-Cx3cr1/ mice
compared with hTau-Cx3cr1+/+ mice (H and L), Cx3cr1/ (G and K), or nontransgenic (Non-Tg) controls (F and J), Scale bar, 20 mm.
(N) Sarkosyl-insoluble and AT8 + MAPT was higher in the hippocampi of hTau-Cx3cr1/ mice than hTau-Cx3cr1+/+ mice.
(O) Numerous Gallyas silver-positive CA3 neurons were detected in the hippocampus of hTau-Cx3cr1/ mice but not hTau-Cx3cr1+/+ mice. Scale bar, 10 mm.
(P–Q) Six-month-old Cx3cr1/, hTau-Cx3cr1+/+, and hTau-Cx3cr1/ mice (n = 8 per age group) were subjected to Y-maze test. While hTau-Cx3cr1/ mice
appeared similar to Cx3cr1/ and hTau-Cx3cr1+/+ mice motor abilities, including the number of arms entered in the Y-maze (P), hTau-Cx3cr1/mice exhibited
a significant deficit (*p < 0.05; one-way ANOVAwith Dunnett’s multiple comparison test at 99% confidence interval) in the percentage of spontaneous alternation
when compared with the control group (Q), indicating deficiencies in spatial working memory.
See also Figure S2.
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Regulation of tau Pathology by CX3CR1Gallyas-positive neurons in the CA3 region of the hippocampus
as well as Gallyas-positive dystrophic neurites were identified in
the 6-month-old hTau-Cx3cr1/ mice but not in age-matched
hTau mice (Figure 2O), nontransgenic mice, or Cx3cr1/22 Neuron 68, 19–31, October 7, 2010 ª2010 Elsevier Inc.controls (data not shown). Furthermore, since Gallyas can
stain other filamentous proteins including neurofilaments,
immunohistochemistry for phosphorylation-dependent (SMI31
antibody) and phosphorylation-independent (SMI32 antibody)
Neuron
Regulation of tau Pathology by CX3CR1neurofilament was performed revealing the lack of detectable
neurofilament aggregates in hTau-Cx3cr1/ mice (data not
shown). Given that MAPT aggregates in the hTau mice do not
appear until 9 months of age (Andorfer et al., 2003), our data
demonstrate that pathologic MAPT aggregation is accelerated
in the hTau-Cx3cr1/ mice.
hTau mice have been reported to exhibit behavioral impair-
ments at 12 months of age, 3 months after the first appearance
of MAPT aggregates. To examine whether CX3CR1 deficiency
resulted in both altered behavior as well as brain pathology at
an earlier time point, 6-month-old hTau-Cx3cr1/, hTau-
Cx3cr1+/+, Cx3cr1/ and nontransgenic mice were tested in
the Y-maze. While the animals were similar in measures of arms
entered (Figure 2P), a measure of general activity, the sponta-
neous alternation ratio, which is a measure of hippocampal-
dependent spatial working memory, was significantly reduced
in the hTau-Cx3cr1/ mice when compared with hTau-
Cx3cr1+/+ and Cx3cr1/ controls (Figure 2Q). Other measures
of motor abilities of the different genotypes, including open field
and rotarod were not significantly different (data not shown).
Taken together, these results demonstrate that CX3CR1 defi-
ciency promotes MAPT phosphorylation and aggregation as
well as behavioral abnormalities in working memory in the hTau
mice.
Enhanced Microglial Activation in hTau-Cx3cr1–/–
Transgenic Mice
To examinewhetherCx3cr1deficiency leads to alteredmicroglial
activation in the hTaumice, brain sectionswere stainedwith ami-
croglia-specific marker, Iba1 as well as CD68, a phagocytic
marker induced uponmicroglial activation. Notably,Cx3cr1 defi-
ciency was associated with Iba1-positive cells that were less
ramified with shorter processes and rounder cell bodies in
hTau-Cx3cr1/micewhencomparedwith hTau, nontransgenic,
or Cx3cr1/ mice (Figures 3A–3H). Quantification of Iba1-posi-
tive cells using fractal dimension analysis (Soltys et al., 2001)
revealed a statistically significant reduction in fractal dimension
in the hTau-Cx3cr1/mice (Figure 3I), consistent with enhanced
microglial activation. Furthermore, CD68 staining was noticeably
elevated in the hTau-Cx3cr1/mice when compared with hTau,
nontransgenic, and Cx3cr1/ controls (Figures 3J–3Q). This
visual impression was confirmed upon quantification of the
densities of CD68 staining (Figure 3R). In addition, both CD11b
and iNOS staining were enhanced in hTau-Cx3cr1/ mice
(Figures S3A and S3B).
To confirm the immunohistochemical findings, the levels of
various transcripts associated with microglial inflammation
were next examined, revealing an increase in the levels of both
CD68 and CD45 (Figures 3S and 3T) in hTau-Cx3cr1/ mice
when compared with controls. As noted above, the 6-month-
old hTau mice displayed elevated levels of NOS2 and MCP1/
CCL2 transcripts (Figures S1I–S1J) compared with nontrans-
genic controls that remained elevated in hTau-Cx3cr1/ mice
(Figures S3C and S3D). These results demonstrate that removal
of CX3CR1 results in both enhanced MAPT phosphorylation,
aggregation, and microglial activation in hTau mice. Because
CX3CR1 is expressed exclusively by microglia in the CNS, these
results suggest that alterations in microglial activation areresponsible for the observed alterations in MAPT phosphoryla-
tion and aggregation.
Elevated p38 MAPK Signaling in hTau-Cx3cr1–/–
Transgenic Mice
To identify the downstream kinase(s) and/or phosphatase path-
ways responsible for the elevated MAPT phosphorylation in the
hTau-Cx3cr1/ mice, the levels of p35 and p25 (regulators of
the Cdk5) (Lew et al., 1994; Tsai et al., 1994), glycogen synthase
kinase 3b (GSK3b) phosphorylated at serine-9 (Sutherland et al.,
1993), p38 MAPK phosphorylated at thr180/tyr182 (Goedert
et al., 1997; Lee et al., 1994), and protein phosphatase 2A
(PP2A) were measured in hippocampal extracts from 6-month-
old hTau-Cx3cr1/ mice and hTau controls. While the levels
of p35/p25, phospho-ser9 GSK3b and PP2A remained unc-
hanged (Figures S2C–S2F), the levels of phospho-p38 MAPK
were significantly elevated in the hippocampus of 6-month-old
hTau-Cx3cr1/ mice when compared with age-matched hTau
controls (Figures S2G and S2H). Previous studies on the hTau
mice demonstrated an elevation in phospho-p38 MAPK at
10 months of age (Kelleher et al., 2007). Finally, activated tran-
scription factor 2 (ATF2), which is phosphorylated at thr71 by
active p38 MAPK, was also significantly increased in 6-month-
old hTau-Cx3cr1/mice when compared with hTau mice alone
(Figures S2G and S2I), suggesting that the levels of both active
p38 MAPK and one of its downstream targets were elevated
and could be responsible for the enhanced phosphorylation
and aggregation of MAPT.
p38 MAPK Promotes MAPT Phosphorylation upon
Exposure to Microglial Factors
We postulated that the enhancement of MAPT phosphorylation
and aggregation as well as p38 MAPK activation in Cx3cr1-defi-
cient hTau mice was due to altered communication between mi-
croglia and neurons. To examine this possibility in greater detail,
wild-type and CX3CR1-deficient microglia were co-cultured in
the bottom compartment of transwell culture dishes with wild-
type primary cortical neurons cultured in the top compartment
for 24 hr prior to evaluation of neuronal cell lysates for alterations
in MAPT phosphorylation (Figure 4A). Co-cultures of neurons
with wild-type microglia significantly induced MAPT phosphory-
lation at the AT8 site compared with neurons alone, while co-
culture of CX3CR1-deficient microglia with neurons further
increased the levels of AT8 MAPT epitopes (Figures 4C
and 4F). Furthermore, the levels of phosphorylated p38 MAPK
was increased in neuronal lysates co-cultured with either wild-
type or CX3CR1-deficient microglia (Figures 4C and 4I). These
data suggest that a soluble factor(s) released from microglia
induces MAPT phosphorylation in neurons and lack of
CX3CR1 in microglia enhances this phenotype.
To confirm and extend these results, primary microglia were
prepared from CX3CR1-deficient mice, conditioned media
(CM) obtained and transferred to primary cortical neurons at
a final concentration of 25% (Figure 4B). Notably, exposure of
primary neurons to CM from Cx3cr1/ microglia resulted in
enhanced levels of MAPT phosphorylation at both the AT8 and
PHF1 sites (Figures 4D, 4E, and 4G). Finally, consistent with
our in vivo as well as co-culture findings, the levels of activatedNeuron 68, 19–31, October 7, 2010 ª2010 Elsevier Inc. 23
Figure 3. CX3CR1 Deficiency Results in Enhanced Microglial Activation hTau Mice
(A–H) Iba1 + microglia in the DG (A–D) and CA3 (E–H) of 6-month-old hTau-Cx3cr1/ mice displayed activated phenotype compared with hTau-Cx3cr1+/+,
Cx3cr1/ and nontransgenic (Non-Tg) controls.
(I)Morphometric analysis of Iba1+microglia fromhTau-Cx3cr1/micedisplayed significantly (n =3 animals per group;mean±SEM; *p< 0.05 for hTau-Cx3cr1/
compared with control groups; one-way ANOVA followed by Dunnett’s pos thoc test) lower fractal dimension value compared with hTau-Cx3cr1+/+, Cx3cr1/,
and non-tg controls.
(J–Q) Increase in the number of CD68 (phagocytic marker) -positive cells in the DG (J–M) and CA3 (N–Q) of hTau-Cx3cr1/mice compared with hTau-Cx3cr1+/+,
Cx3cr1/, or non-tg controls.
(R) Quantification of the CD68+ density revealed a significant increase (n = 3mice per group; mean ± SEM; ***p < 0.0001; one-way ANOVA followed by Tukey post
hoc test) in hTau-Cx3cr1+/+ mice when compared with hTau-Cx3cr1+/+, Cx3cr1/, or non-tg controls. Scale bar, 10 mm.
(S and T) Quantitative real-time PCR analysis for CD45 and CD68 transcripts revealed a significant increase (normalized to nontransgenics; n = 3 mice per group;
mean ±SD; *p < 0.05, **p < 0.01; one-way ANOVA followed byTukey post hoc test) in bothCD45 andCD68 in the hemibrains of 6-month-old hTau-Cx3cr1/mice
compared with age-matched controls.
See also Figure S3.
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Regulation of tau Pathology by CX3CR1p38 MAPK were also increased in neurons exposed to CM from
the Cx3cr1-deficient microglia (Figures 4D and 4H). The effects
of the microglial CM could be blocked by heat inactivation
(Figures 4D–4H), suggesting the factor(s) responsible was likely
proteinaceous. Significantly, the effects of CX3CR1-deficient mi-
croglial CM on both p38 MAPK activation and MAPT phosphor-
ylation could be blocked by 30 min preincubating neurons with
a specific p38 MAPK inhibitor, SB203580 (Cuenda et al., 1995;
Figures 4D–4H), indicating that the enhancement of MAPT phos-
phorylation occurred via a p38 MAPK-dependent pathway.
Consistent with this, phosphorylation of ATF2 at thr71 was also24 Neuron 68, 19–31, October 7, 2010 ª2010 Elsevier Inc.elevated in neurons treated with microglial CM and blocked by
treatment with SB203580 (Figures 4J and 4K). Taken together,
our in vitro and in vivo studies suggest that a microglia-derived
soluble factor(s) induces a p38 MAPK-dependent increase in
neuronal MAPT phosphorylation that is further enhanced in
Cx3cr1-deficient microglia.
Induction of MAPT Phosphorylation Is Dependent upon
TLR4 and IL-1 Signaling
Several previous in vitro studies demonstrated that micro-
glial-derived interleukin-1b (IL-1b) could induce MAPT
Figure 4. Microglial-Derived Soluble Factors Induce MAPT Phosphorylation in Neurons via p38 MAPK Pathway
(A and B) Schematics displaying details of microglia-neuron co-culture experiment (A) and microglia conditioned media (CM) treatment on primary neurons (B).
Nontransgenic controls (Cx3cr1+/+) or Cx3cr1/ microglia were co-cultured with 21 DIV primary cortical neurons derived from nontransgenic (Cx3cr1+/+)
embryos for 24 hr and the neuronal lysates were processed for biochemical analysis. For the CM experiments, 21 DIV Cx3cr1+/+ neurons were treated with
25% (‘‘+’’) Cx3cr1/ microglial CM for 24 hr prior to biochemical analysis of neuronal lysates. CM from empty wells (‘‘’’) served as a negative control.
(C, F, and I) Neurons cocultured with Cx3cr1+/+ microglia displayed significant induction of AT8 site MAPT phosphorylation (C and F) and p38 MAPK activation
(C and I) compared with neurons co-cultured without microglia. AT8 site phosphorylation was further enhanced when the neurons were co-cultured with
Cx3cr1/microglia (n = 3 independent cultures; mean ± SEM of IDV ratios; *p < 0.05, **p < 0.01; one-way ANOVA followed by Tukey post hoc test).
(D, E, G, and H) Cx3cr1/microglial CM significantly induced neuronal AT8 and PHF1 site MAPT phosphorylation and p38 MAPK (phospho-thr180/tyr182) acti-
vation. Heat inactivation of microglial CM (microwaved until boiling and cooled) prior to neuronal treatment blocked neuronal MAPT phosphorylation and p38
MAPK activation. Pretreatment (30 min) of primary neurons with SB203580, a p38 MAPK inhibitor, also significantly blocked the effects of microglial CM (n = 3
independent cultures; mean ± SEM of IDV ratios; *p < 0.05, **p < 0.01; one-way ANOVA-Dunnett’s post hoc test for AT8 and Tukey post hoc test for PHF1 and
phospho-p38 MAPK).
(J andK) Levels of activated-ATF2 (phospho-thr71) were elevated inmicroglia CM treated neuronal lysates andwasblockedbySB203580pretreatment. All exper-
iments were performed in duplicates in three independent cultures.
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pathway (Hartzler et al., 2002; Li et al., 2003; Sheng et al.,
2001). In addition, previous findings from our laboratory demon-
strated that the neurotoxic effects of LPS stimulated CX3CR1-
deficient microglia was mediated in part by IL-1b (Cardona
et al., 2006). To determine if theMAPT phosphorylation observed
upon LPS administration is dependent upon TLR4 and IL-1
signaling, we performed an additional in vivo LPS experiment.
H-LPS (10 mg/kg) was administered to wild-type, Tlr4/, and
interleukin-1 receptor type I knockout (Il1r1/) mice and endog-enous MAPT phosphorylation was analyzed by western blot
analysis. While H-LPS induces AT8 and AT180 site phosphoryla-
tionofMAPT inCx3cr1+/+andCx3cr1/mice, theseeffectswere
completely blocked in both Tlr4/ (Figures 5A and 5B) and
Il1r1/mice (Figures 5C and 5D). The block in MAPT phosphor-
ylation in the Tlr4/ mice demonstrates that the effects of LPS
act through the canonical TLR4 signaling pathway within the
brain, while the block of MAPT phosphorylation in the Il1r1/
mice suggests that one of the cytokines responsible for induction
of MAPT phosphorylation is IL-1. To examine whether microglialNeuron 68, 19–31, October 7, 2010 ª2010 Elsevier Inc. 25
Figure 5. IL-1R1 and TLR4 Deficiency Blocks LPS-
Induced MAPT Phosphorylation
Two-month-old Cx3cr1+/+, Cx3cr1/, Tlr4/ (A and B), and
Il1r1/ (C and D) mice were injected with either a single dose of
vehicle or high-dose LPS (10 mg/kg).
(A and C) Western immunoblot of hippocampal extracts shows
LPS induces dose-dependent increases in AT8 and AT180 site
phosphorylation of endogenous mouse MAPT in Cx3cr1+/+ mice,
that was further elevated in Cx3cr1/ mice, but blocked in
Tlr4/ (A) and Il1r1/ (C) mice to levels similar to that observed
in vehicle-injected Cx3cr1+/+ mice. Total MAPT and GAPDH levels
were similar across all samples.
(B and D) Quantification of western blots revealed a statistically
significant decrease in the ratios of AT8/GAPDH and AT180/
GAPDH (data not shown) in the IL-1R1/ (n = 3) and TLR4/
(n = 3) mice injected with H-LPS when compared with H-LPS-in-
jected treated Cx3cr1+/+ mice (n = 4; mean ± SEM of integrated
density value – IDV ratio; *p < 0.05; unpaired t test).
(E–G) IL-1 receptor antagonist (IL-1-RA/Kineret) attenuates micro-
glial-induced neuronal MAPT phosphorylation. (E) 21 DIV primary
cortical neurons were pretreated (15 min) with vehicle () or
50 ng/ml IL-1-RA (Kineret) prior to incubation with conditioned
media (CM) from Cx3cr1/ microglia. Twenty-four hours after
the incubation, the neuronal lysates were probed for AT8, total
MAPT (Tau5), phospho-p38 MAPK, total p38 MAPK, and GAPDH.
Note reduction in AT8 and phospho-p38 MAPK-immunoreactive
bands in IL-1-RA-treated neurons. (F and G) Quantification of the
AT8/Total MAPT and phospho-p38 MAPK/total p38 MAPK ratios
revealed more than 4-fold reduction in the AT8 site phosphoryla-
tion (F) and statistically significant (*p < 0.05; mean ± SEM; n = 3;
unpaired t test) reduction in phospho-p38 MAPK levels (G) as
a result of Kineret pretreatment. All experiments were performed
in duplicates in three independent cultures.
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p38 MAPK, and promote MAPT phosphorylation, we turned to
the in vitro culture system (Figure 4B) in which CM from
CX3CR1-deficient microglia was exposed to primary cortical
neurons. Notably, the effects of microglial conditioned media
on activation of p38 MAPK and neuronal MAPT phosphorylation
was attenuated by pretreatment of the neurons with Kineret, an
IL-1R antagonist (Figures 5E–5G). In summary, our data suggest
microglially derived IL-1 can promote p38 MAPK activation and
lead to enhanced MAPT phosphorylation within neurons.
DISCUSSION
In the current studies, we demonstrated that microglial-medi-
ated neuroinflammation induces MAPT phosphorylation in
several different models: a single LPS injection model of modest26 Neuron 68, 19–31, October 7, 2010 ª2010 Elsevier Inc.systemic inflammation, the hTau mouse model of tau-
opathy mated toCx3cr1/mice and an in vitro micro-
glial/neuronal culture system.
While other studies have linked microglial activation
to MAPT phosphorylation, a majority of these studies
were performed in vitro or were correlational in nature
in postmortem tissue. The only two previous
in vivo studies to address the relationship between
neuroinflammation and MAPT phosphorylation andaggregation was a study examining the effects of LPS adminis-
tration in the 3xTg mouse model of AD and a separate study on
the effects of the immunosuppressant drug FK506 in P301S
transgenic mice. However, the 3xTg mice contains mutant
APP, PSEN1, as well as MAPT transgenes, making it difficult to
assess the direct contribution of LPS to MAPT pathology, as mi-
croglial activation is also observed in response to the aggressive
beta-amyloid (Ab) deposition observed in this model. In addition,
the effects of LPS can act through numerous cell types within the
brain. By contrast, the P301S study provided the first evidence
that microglial neuroinflammation precedes MAPT pathology (in
the absence of Ab pathology) and that intervention with FK506
could ameliorate MAPT pathology and increase life span (Yosh-
iyama et al., 2007). While these studies suggested a links
between microglial neuroinflammation and MAPT pathology,
the current study documents the effects of a specific microglial
Figure 6. Model of Fractalkine (CX3CL1/
CX3CR1) Signaling in Neurodegenerative
Tauopathies
(A) In theCNS, the chemokine fractalkine (CX3CL1)
is expressed by neurons and cleaved by the disin-
tegrin and metalloproteases (ADAM10 and
ADAM17) to release cleaved soluble CX3CL1,
which binds to the G-coupled transmembrane
receptor (CX3CR1) present on microglia and regu-
lates microglial activity. Lipopolysaccharide (LPS)
inducesmicroglial activation, while neuronal stress
(such as overexpression and somatodendritic
accumulation of human MAPT in case of hTau)
results in enhanced release of CX3CL1. An interac-
tion between fractalkine (CX3CL1) and its receptor
(CX3CR1) downregulates microglial activity and
dampens the toxic effects of activated microglia.
(B) Lack of CX3CR1 (Cx3cr1/) in microglia
disrupts CX3CL1-CX3CR1 communication
(dashed blue arrow), dysregulates microglial
activity induced by LPS or neuronal stress (human
MAPT overexpression in hTaumice), and results in
enhanced release of soluble factors (including IL-1)
from activated microglia. IL-1 can subsequently
bind to its receptor (IL-1R1) on neurons and induce
activation of neuronal p38 MAPK thus leading to
enhanced phosphorylation and aggregation of
MAPT. Notably, this molecular mechanism would
lead to a feed-forward induction of MAPT phos-
phorylation/aggregation and microglial activation.
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nistic insights into the downstream signaling molecules.
The present study demonstrates that a single dose of LPS,
administered peripherally, is sufficient to induce MAPT hyper-
phosphorylation. LPS is an endotoxin that is part of the outer
wall of Gram-negative bacteria and can induce systemic inflam-
mation via engagement of TLR4 (Lien et al., 2000). LPS has also
been utilized asmodel to examine the role neuroinflammation via
either peripheral administration in systemic inflammation or
direct administration into the brain (Hauss-Wegrzyniak et al.,
1998). Depending upon the dose of LPS, the route of administra-
tion, the time frame, and the model examined, LPS can induce
either neurodegeneration or neuroprotection with both short-
term (hours to days) and long-term (months to years) effects.
The LPS paradigm we have employed to examine the effects
of induction of systemic inflammation has been widely utilized
in numerous animal models of neurodegeneration (Cunningham
et al., 2005, 2009; Masocha, 2009; Qin et al., 2007). Notably,
several recent studies have suggested that the acute effects of
LPS can have long-lasting effects (months to years) within the
CNS (Masocha, 2009; Qin et al., 2007). Our studies demonstrate
a graded response to LPSwith increasedMAPT phosphorylation
that is dependent upon the dose of LPS and deficiency of
CX3CR1. Furthermore, either Tlr4 or Il1r1 deficiency blocked
the enhanced MAPT phosphorylation observed upon LPS
administration, demonstrating that LPS-induced MAPT phos-
phorylation is acting through a canonical inflammatory pathway
mediated in part by IL-1. In addition, in vitro studies demon-
strated that blocking IL-1 signaling with an IL-1 receptor antag-
onist reduced both p38 MAPK activation as well as MAPT phos-phorylation within neurons. Future studies will be required to
examine the relative contribution of IL-1a versus IL-1b and to
determine whether the enhanced MAPT phosphorylation and
aggregation observed in CX3CR1-deficient hTau mice is also
dependent upon IL-1-p38 MAPK signaling.
Previous studies demonstrated that hTau mice develop
age-related MAPT pathology (Andorfer et al., 2003) and neuro-
degeneration (Andorfer et al., 2005). In the current studies, we
document that hTau mice develop age-related alterations in
microglia activation at 12–18 months of age. This is consistent
with several other recent observations in the hTau mice (Kelleher
et al., 2007; Noble et al., 2009) as well as other mouse model of
tauopathies (Kitazawa et al., 2005; Yoshiyama et al., 2007),
suggesting that robust microglia activation occurs upon devel-
opment of extensive MAPT pathology. In addition, our studies
suggest that at 6 months of age, an age at which there is minimal
development of MAPT aggregates, there are already alterations
in expression of several cytokines and chemokines, including
CCL2, NOS2, and most notably CX3CL1. CX3CL1 is produced
by neurons in the CNS and signals directly to the CX3CR1
receptor, which is exclusively produced by microglia. Finally,
consistent with the findings in the 3xTg mouse model, LPS
administration to hTau mice induced enhanced MAPT phos-
phorylation (Kitazawa et al., 2005).
CX3CL1 and its cognate receptor, CX3CR1, play an important
role in neuroinflammation via paracrine signaling between
neurons andmicroglia (Figure 6). Previous studies from our labo-
ratory (Cardona et al., 2006) as well as others (Jung et al., 2000)
demonstrated that CX3CR1 deficiency alone does not lead to
acute microglial activation or neurodegeneration. However, inNeuron 68, 19–31, October 7, 2010 ª2010 Elsevier Inc. 27
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deficiency leads to enhanced neurodegeneration (Cardona et al.,
2006), while conversely in mouse models of stroke, CX3CR1
deficiency lead to neuroprotection (Denes et al., 2008).
Notably, a recent study by Fuhrmann et al. (2010) suggested
that CX3CR1 deficiency could prevent neuronal loss in the
3xTgmousemodel of AD. A 1.8% loss of neurons in cortical layer
II per month observed in the 3xTg mouse model detected by two
photon microscopy was prevented in the CX3CR1-deficient
3xTg animals. While this study suggested that CX3CR1 defi-
ciency could modulate phenotypes in an ADmousemodel, there
are a number of important differences between the two studies,
their endpoints, and their conclusions.
First, the 3xTg mice exhibits both Ab and MAPT pathologies
due to the inclusion of three different mutant human transgenes
(APP, PSEN1, and MAPT) that causes AD and/or FTD. Because
of this transgenic strategy, it remains difficult to attribute the
effects of CX3CR1 deficiency to specific alterations in Ab or
MAPT pathologies. Notably, we have recently completed a sepa-
rate study examining the effects of CX3CR1 deficiency on Ab
pathologies in two different mouse models of AD and demon-
strate that blocking CX3CL1-CX3CR1 signaling actually reduces
Ab pathologies via a mechanism involving alterations in micro-
glial phagocytosis of extracellular Ab aggregates (Lee et al.,
2010). Thus, taken together, our results suggest that CX3CR1
deficiency has opposing effects on the two primary pathologies
of AD, extracellular Ab plaques, and intracellular MAPT aggre-
gates, information that could not be discerned in the Fuhrmann
et al. (2010) studies.
Second, Fuhrmann et al. (2010) examined CX3CR1-deficient
3xTg animals at 4–6months of age, which is just prior to substan-
tial extracellular Ab deposits exhibited in this model and at least
6–8 months prior to the first appearance of alterations in MAPT
phosphorylation and aggregation (Oddo et al., 2003). Notably,
the authors also report that there are no observable alterations
inMAPT phosphorylation in 4- to 6-month-old CX3CR1-deficient
3xTg mice. In addition, due to restrictions in live imaging within
the brain by two photon microscopy, the neuronal loss detected
by Fuhrmann et al. (2010) was observed in the outer layers of the
cortex and not within the hippocampus, where the initial alter-
ations in MAPT phosphorylation and aggregation were observed
in the hTau mouse model and have also been reported in the
3xTg mouse model. Because of this, the Fuhrmann et al.
(2010) study focuses on the abundant intracellular Ab present
at this age within this cortical neuronal population in the 3xTg
mice as a potential neurotoxic trigger for the neuronal loss that
can be blocked by CX3CR1 deficiency. How these results trans-
late to effects on extracellular Ab deposition, similar to that pub-
lished by Lee et al. (2010) and intracellular MAPT aggregates, as
presented here, remain to be determined.
Third, most of the transgenic mouse models of AD, including
the 3xTg mice do not exhibit robust age-related neurodegener-
ation (for review, see McGowan et al., 2006), as assessed by
other postmortem methods utilized to detect neuronal cell
loss. Thus, it remains to be determined how the neuronal loss
observed by Fuhrmann et al. (2010) via two photon microscopy
relates to the long-term Ab toxicity observed in the AD mouse
models.28 Neuron 68, 19–31, October 7, 2010 ª2010 Elsevier Inc.Fourth, our studies suggest that CX3CR1 deficiency has
opposing effects on Ab and MAPT pathologies (Lee et al.,
2010). Given increasing evidence that Ab pathologies precede
MAPT pathologies by as much as 10 years in humans (Perrin
et al., 2009) our studies strongly suggest that blocking
CX3CL1/CX3CR1 signaling has opposing effects at different
stages of disease progression. Thus, while CX3CR1 deficiency
at early stages of intracellular Ab pathology (Fuhrmann et al.,
2010) and extracellular Ab pathology (Lee et al., 2010) may be
protective, the effects of CX3CR1 deficiency are deleterious as
the disease progresses toward development of enhancedmicro-
glia-mediated neuroinflammation and/or MAPT aggregation.
Future studies will be required to assess the validity of this
hypothesis in additional disease-relevant animal models, as
well as assess the effects on microglial phenotypes at different
stages of disease progression.
Finally, the present study provides mechanistic links between
CX3CR1 and specific AD pathologies and signaling pathways.
CX3CR1 deficiency has specific effects on MAPT phosphoryla-
tion and aggregation, microglial activation, and behavior in the
hTau mouse model. In addition, these studies link CX3CR1 defi-
ciency to the release of microglia factors (including IL-1) that
subsequently induces p38 MAPK and MAPT phosphorylation
within neurons.
Interestingly, our previous studies demonstrated that adminis-
tration of LPS to Cx3cr1/ mice induces neurodegeneration
that is also dependent upon IL-1 signaling (Cardona et al.,
2006), suggesting that IL-1 may represent as an important
signaling molecule between microglia and neurons. Notably,
the relevance of CX3CL1-CX3CR1 signaling to human neurode-
generation has been highlighted by the identification of V249I
and T280M polymorphisms in CX3CR1 that are associated
with human age-related macular degeneration (Combadiere
et al., 2007). The current study extends these observations and
provides evidence that CX3CL1-CX3CR1 signaling plays a role
in the development of tauopathies, as CX3CR1-deficient hTau
mice exhibit enhanced microglial activation, pronounced
MAPT hyperphosphorylation, and pathology as well as memory
disturbances (Figure 6). These results also suggest that
CX3CL1-CX3CR1 signaling may provide a novel therapeutic
target for tauopathies (Figure 6).
Several different studies have provided evidence that p38
MAPK is one of the MAPT kinases that links neuroinflammation
and MAPT phosphorylation in tauopathies (Hartzler et al.,
2002; Hensley et al., 1999; Sun et al., 2003). In the present
studies, we observed increased levels of activated p38 MAPK
and ATF2 in the brains of CX3CR1-deficient hTau mice, but not
other established MAPT kinases. Furthermore, our in vitro
studies demonstrated that soluble factors released by microglia
(and enhanced in CX3CR1-deficient microglia) induces MAPT
phosphorylation in cultured neurons that is dependent upon
p38 MAPK activity and can be blocked by an IL-1 receptor
antagonist.
In conclusion, this study demonstrates that altered micro-
glia activation plays a direct role in modulating the hyperphos-
phorylation and aggregation of MAPT within neurons and
suggests potential strategies for therapeutic intervention in
tauopathies.
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Animals
hTau (Andorfer et al., 2003), Il1r1/, Tlr4/, and Cx3cr1/ (Jung et al., 2000)
mice were in C57BL/6J genetic background and were obtained from the Jack-
son Laboratory and Dan Littman (HHMI, New York University School of Medi-
cine). Experimental protocols were performed in accordance with US National
Institutes of Health guidelines on animal care and were approved by the Cleve-
land Clinic Institutional Animal Care and Use Committee.
Antibodies
MAPT Antibodies
Mouse monoclonal antibodies AT8, AT180 (Pierce) and Tau5 (Invitrogen);
PHF-1, CP13, TG3 (provided by Peter Davies, Albert Einstein College of Medi-
cine).
Inflammatory Markers
Rabbit polyclonal antibody against ionized calcium binding adaptor molecule
1 (Iba1) (Wako); rat monoclonal antibody against CD68 (Serotec). Mouse
monoclonal antibodies against CD11b/Mac-1 (Chemicon/Millipore) and
iNOS (Transduction Laboratories).
Other Antibodies
Mouse monoclonal antibody against GAPDH; rabbit polyclonal antibodies
against activated ATF-2 (CRE-BP1) phosphorylated at thr71, total p38
MAPK, and activated p38 MAPK (phospho-thr180/tyr182) were from Cell
Signaling; mouse monoclonal antibody against Cdk5 regulators p35/p25
(05-380; Millipore), rabbit monoclonal antibody against GSK3b-phospho-
ser9 (04-1075; Millipore); rabbit monoclonal antibody to PP2A C-subunit
(52F8; 2259; Cell Signaling).
LPS Administration
Vehicle (Veh, Hank’s balanced saline solution) or lipopolysaccharide (LPS;
Sigma-Aldrich, USA) at two concentrations (1 mg/kg or 10 mg/kg body weight
L-LPS or H-LPS, respectively; intraperitoneal; single dose) was injected into
2-month-old nontransgenic C57BL/6, Cx3cr1/, Il1r1/, and Tlr4/ mice.
Two-month-old hTau mice received LPS at 1 mg/kg b.w. The doses of LPS
selected for the presented study is based on a study, which reported sublethal
(<5 mg/kg b.w) and lethal (>5 mg/kg b.w) LPS doses and that the latter dose
produced neurodegeneration and chronic microglial activation, which could
be observed 10 months postinjection (Qin et al., 2007). After 24 hr, the mice
were sacrificed and the hippocampi from left hemisphere were processed
for biochemical analysis, and the entire right hemisphere was drop-fixed in
4% paraformaldehyde and processed for neuropathological analysis.
SDS-PAGE and Western Immunoblotting
Hippocampal lysates were prepared by homogenizing in Tissue-Protein
Extraction Reagent (T-PER, 78510; Pierce) with protease (P8340 Sigma-Al-
drich) and phosphatase (P5726; Sigma-Aldrich) inhibitor cocktails. Protein
(20 mg) was resolved in 4%–12% Bis-Tris Novex NuPage gels (Invitrogen)
and transferred to PVDF membrane, blocked (in 5%milk) and incubated over-
night in primary antibodies (AT8 1:5000; AT180 1:5000; PHF-1 1:10,000; Tau5
1:10,000; GAPDH 1:20,000; phospho-p38 MAPK, total p38 MAPK, phospho-
ATF-2 were used at 1:1000) following by respective secondary antibodies.
Membranes were developed using ECL reagent (NEL101001EA; Perkin Elmer)
and immunoreactive bands were quantified in AlphaEaseFC Software (Alpha
Innotech Corporation).
Immunohistochemistry
Free-floating sections were processed for standard immunohistochemistry or
immunofluorescence staining. Primary antibodies were used are at following
dilution; AT8, AT180, CD68, at 1:200; TG3 and CP13 1:100; Iba1 1:500; incu-
bated overnight at 4C. Secondary antibodies (1:500) conjugated to either
biotin (for immunohistochemistry from Vector Laboratories) or Alexa Fluor
dyes (for immunofluorescence from Invitrogen) were used. Sections then
were either mounted in DAPI Hardset Reagent (for immunofluorescence) or
incubated with Avidin:Biotinylated enzyme Complex (ABC reagent, Vector
Laboratories; for immunohistochemistry) reagent for 1 hr at room temperature.
The immunoreactive signals were revealed by developing sections in Sigma-Fast with (for Iba1, CD68, CD11b, and iNOS) or without (for all MAPT anti-
bodies) the metal enhancer.
Morphometric Analysis of Microglial Morphology and CD68 Density
Fractal dimension analysis to determine the activation state of microglia was
performed on Iba1-stained images acquired at 320 objective using Image-
Pro Plus software as described before (Soltys et al., 2001; Varvel et al.,
2009). To quantify the density of CD68-immunoreactive cells/structures, we
referred earlier methods (Jimenez-Andrade et al., 2006) with slight modifica-
tion. In brief, CD68-stained images were background subtracted and normal-
ized (segmentation and threshold setting) and the immunoreactive densities
were determined using a specific Image-Pro Plus macro (‘‘Density’’) and
expressed as mean ± SEM per each group. For both Iba1 and CD68 quantifi-
cation three sections per animal; three eight bit RGB digital images at the
dentate gyrus and CA3 regions per animal; n = 3 animals).
Primary Cortical Neuronal Cultures
Neuronal cultures were prepared from E16.5 C57BL/6J wild-type mouse
embryos as described before (Bhaskar et al., 2009). Specifically, primary
cortical neurons were seeded on poly-L-lysine coated coverslips at a density
of 1.6 3 105 cells/well in six-well plate (for co-culture experiments). Alterna-
tively, cells were also plated at 1.6 3 105 cells/well directly onto poly-L-lysine
coated six-well plate without coverslips (for conditionedmedia experiment). All
cultures were grown for 21 days in vitro (DIV) at 37C in humidified 5% CO2/
95% air prior to any treatment.
Primary Microglial Culture
Microglial cultureswere prepared frompostnatal day 3 (P3) pups fromCx3cr1+/+
or Cx3cr1/ genotypes as described before (Saura et al., 2003). Specifically,
mixed glial cells were seeded at a density of 1.0 3 105 to 1.2 3 105 cells/cm2
to obtain approximately 6 3 104 to 8 3 105 microglial cells/cm2 after removal
of astrocyte layer at 14th day. Furthermore, the DMEM-F12mediawas replaced
withNeurobasalmedia (with noB27supplements) 24 hr prior to the co-culture or
conditioned media experiment to match the culture media with that of primary
neurons.
Neuron-Microglia Cocultures
Primary neuronal and microglial cultures were prepared as described above.
Twenty-one DIV primary cortical neurons grown on a coverslip were placed
inside a six-well microplate insert, which has a 0.02 mm Anopore membrane
in the bottom (161395; Nunc) and allows diffusion of soluble factors into the
media. The inserts were then placed inside individual wells in six-well plate,
which had Cxcr1+/+, Cx3cr1/, or no primary microglia, and incubated for
24 hr. The neurons were lysed in 13 Lithium dodecyl sulfate (LDS) buffer,
and the proteins were resolved in 4%–12% Bis-Tris NuPage gels (Invitrogen)
and western immunoblotting was performed as described above. All the
experiments were done in triplicates with independent cultures.
Microglial Conditioned Media Treatment
One fourth of the media (25%) present in the primary neurons at 21 DIV was
replaced with equal volume of conditioned media (CM) obtained from primary
microglial cultures. CM from no microglial cells served as controls. For the
analysis of heat inactivation, the CM was microwaved until boiling and cooled
and applied to neurons. For the analysis of specific p38 MAPK inhibitors, 21
DIV cortical neurons were preincubated for 30 min or 15 min with 20 mM
SB203580 (S8307; Sigma-Aldrich) or IL-1RA (Kineret, 50 ng/ml; Amgen),
respectively, prior to CM treatment. After 24 hr incubation, the neuronal lysates
were prepared and western blotted as mentioned above. All the experiments
were done in triplicates with independent cultures.
Gene Expression Analysis
RNA from the hemibrain was extracted using the Tri Reagent as described by
the manufacturer (Invitrogen). Total RNA (50 ng/ml) was converted to cDNA
using the High Capacity cDNA Reverse Transcription kit (Applied Biosystems
Inc., ABI) and amplified using specific TaqMan probes (see Supplemental
Information) and GAPDH as a house keeping gene for normalization, on the
ABI 7300 Real-Time PCR System.Neuron 68, 19–31, October 7, 2010 ª2010 Elsevier Inc. 29
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Sarkosyl-insoluble fraction of MAPT was isolated from hippocampal tissues as
described before (Greenberg and Davies, 1990) with minor modifications. The
experimental details are provided in the Supplemental Information.
Gallyas Silver Staining
The Gallyas silver staining on 30 mm free-floating sections were performed as
described previously (Braak and Braak, 1991).
Behavioral Analysis
A symmetrical Y maze was used to evaluate spatial working memory (Hughes,
2004). Experimental details and calculation of percent spontaneous alterna-
tions are mentioned in the Supplemental Information.
Statistical Analysis
Data are presented as mean ± SEM. Unless otherwise noted, the Student’s t
test (two-tailed; unpaired) at 95% confidence interval (for two group compar-
ison) or one-way ANOVA followed by Tukey or Dunnett’s post hoc test
(for multiple comparisons) was utilized for statistical analysis. Statistical signif-
icance was determined at p < 0.05.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Experimental Procedures and three figures
and can be found online at doi:10.1016/j.neuron.2010.08.023.
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